Both Cerus Corporation (NASDAQ:CERS) and Dare Bioscience Inc. (NASDAQ:DARE) are Biotechnology companies, competing one another. We will compare their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus Corporation	60.91M	13.81	57.56M	-0.42	0.00
Dare Bioscience Inc.	N/A	0.00	22.95M	-2.92	0.00

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 shows Cerus Corporation and Dare Bioscience Inc.’s return on assets, net margins and return on equity.

	Net Margins	Return on Equity	Return on Assets
Cerus Corporation	-94.50%	-67.9%	-37.4%
Dare Bioscience Inc.	0.00%	-180.3%	-166.4%

Risk & Volatility

A 1.45 beta indicates that Cerus Corporation is 45.00% more volatile compared to Standard and Poor’s 500. Dare Bioscience Inc. on the other hand, has 2.25 beta which makes it 125.00% more volatile compared to Standard and Poor’s 500.

Liquidity

Cerus Corporation’s Current Ratio and Quick Ratio are 3.5 and 3.2 respectively. The Current Ratio and Quick Ratio of its competitor Dare Bioscience Inc. are 8.5 and 8.5 respectively. Dare Bioscience Inc. therefore has a better chance of paying off short and long-term obligations compared to Cerus Corporation.

Analyst Ratings

The table shown features the ratings and recommendations for Cerus Corporation and Dare Bioscience Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Cerus Corporation	0	0	1	3.00
Dare Bioscience Inc.	0	0	0	0.00

Cerus Corporation’s average target price is $9, while its potential upside is 46.58%.

Insider and Institutional Ownership

Institutional investors held 68.4% of Cerus Corporation shares and 11.4% of Dare Bioscience Inc. shares. Insiders held roughly 0.5% of Cerus Corporation’s shares. Insiders Competitively, held 23.7% of Dare Bioscience Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Cerus Corporation	2.49%	10.57%	24.81%	-12.95%	52.55%	29.98%
Dare Bioscience Inc.	5.95%	8.86%	1.14%	-13.59%	-29.37%	25.26%

For the past year Cerus Corporation has stronger performance than Dare Bioscience Inc.

Summary

On 7 of the 10 factors Cerus Corporation beats Dare Bioscience Inc.

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The companyÂ’s INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was founded in 1991 and is headquartered in Concord, California.

Daré Bioscience, Inc. develops and commercializes product for women’s reproductive health, Ovaprene. The company was incorporated in 2015 and is based in La Jolla, California.